Savara Inc

-0.09 (-4.41%)
5:33:52 PM EDT: $1.86 -0.09 (-4.62%)
Layoffs, Regulatory, Other Pre-Announcement

Savara Reports Phase 3 AVAIL Trail Missed Main Goal, Stopping Further Development Of AeroVanc

Published: 12/10/2020 13:34 GMT
Savara Inc (SVRA) - Savara Provides Pipeline and Business Update.
Savara Inc - Announces Phase 3 Avail Trial Missed Primary Endpoint, Stopping Further Development of Aerovanc.
Savara Inc - Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent Ceo.
Savara Inc - Reduces Operating Expenses to Align With Streamlined Development Programs.
Savara Inc - Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex in Apap.
Savara Inc - Revises Study-start Guidance for Impala 2 Clinical Trial to Q2 2021.
Savara Inc Says Implemented a Plan to Reduce Overall Operating Expenses, Including a Reduction in Workforce.
Savara Inc - Expects to End Year With Cash, Cash Equivalents, and Short-term Investments of Approximately $82 Million and Debt of About $25 Million.
Savara Inc Says Still in Process of Determining Final Results for Q4 of 2020.
Savara Inc - Discontinued Apulmiq Clinical Development Program.